CTMX - CytomX Therapeutics

-

$undefined

N/A

(N/A)

CytomX Therapeutics NasdaqGS:CTMX CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Location: 151 Oyster Point Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.cytomx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

131.4M

Cash

79.89M

Avg Qtr Burn

-20.31M

Short % of Float

29.07%

Insider Ownership

0.83%

Institutional Own.

51.06%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CX-2051 Details
Cancer, Metastatic colorectal cancer

Phase 1a

Data readout

CX-801 + KEYTRUDA Details
Cancer, Solid tumor/s, Melanoma

Phase 1a

Data readout

CX-904 (EGFRxCD3) Details
Cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Praluzatamab ravtansine (CX-2009) (anti-CD166) Details
Cancer, HER2-expressing cancers, Breast cancer

Failed

Discontinued

CX-2029 (PDC directed against CD71) Details
Non-small cell lung carcinoma, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued